Vexev

What Vexev does

Vexev is an Australian medical technology company developing the VxWave Ultrasound Imaging System, a robotic tomographic ultrasound platform designed for upper-limb vascular imaging and arteriovenous (AV) fistula mapping in dialysis patients. The system integrates custom in-house robotics, proprietary ultrasound signal processing, machine learning, and computational fluid dynamics to produce 3D vascular models and detailed flow analyses at the point of care, without ionizing radiation and without requiring an operator to manually guide the probe. Vexev was founded by Dr. John Carroll and Dr. Eamonn Colley at the University of New South Wales and is headquartered in Surry Hills, NSW, Australia.

The company operates as a clinical-stage, pre-revenue medical device business. VxWave is currently limited to investigational use only and is not cleared for sale by the FDA or any other regulatory authority; no pricing is publicly disclosed. The go-to-market motion is an enterprise field-sales approach targeting large dialysis provider networks, anchored by a multi-center feasibility study (CANSCAN) with U.S. Renal Care, the third-largest U.S. dialysis provider. The trial completed enrollment of 115-120 patients in July 2025 and met primary endpoints in November 2025. The principal customer segment is dialysis clinics and interventional nephrology practices performing AV fistula mapping, with a secondary, longer-term opportunity in proactive vascular health monitoring for high-risk patients.

Vexev is backed by Blackbird Ventures (lead investor across multiple rounds), Neotribe Ventures, and Startmate, with cumulative disclosed funding of approximately $11M+ between 2018 and 2022. The leadership team includes co-founders Carroll and Colley, Chief Medical Officer Dr. Shannon Thomas, and Senior Robotics Engineer Deanna Hood. The company supports its commercialization pathway through peer-reviewed publications (Journal of Vascular Access, November 2023), industry conference presence (ROSCON 2024 keynote), and earned media in healthcare industry outlets (Mass Device, PR Newswire).

Name

Vexev

Legal name

Vexev Pty Ltd

Website

https://vexev.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Vexev is an Australian clinical-stage medical device company developing the VxWave robotic tomographic ultrasound system for AV fistula mapping and vascular imaging in dialysis patients. It targets dialysis provider networks, anchored by a CANSCAN feasibility trial with U.S. Renal Care, and remains pre-revenue pending FDA clearance.

Ownership category

akta.pro rank

Product category

Vascular Medical Imaging

NAICS

Diagnostic Imaging Centers (621512), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)

akta.pro secondary industries

Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC), Condition-specific Digital Therapeutics (DTx) (HLACANAA)

Keywords

• Vascular ultrasound imaging
• Robotic diagnostics
• Dialysis care
• Medical imaging systems
• Cardiovascular diagnostics

Headquarters

HQ city

Surry Hills

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (Future): Vexev's VxWave system is currently limited to investigational use only and not cleared for sale by the FDA in the United States or any other regulatory authority. Revenue generation is anticipated upon regulatory approval and commercialization.
2. Clinical Trial Partnerships (Current): The company generates value through clinical trial partnerships with healthcare providers like U.S. Renal Care, which serve as both validation pathways and potential long-term customer relationships for future commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Vexev develops the VxWave Ultrasound Imaging System, a robotic tomographic ultrasound platform designed for upper limb vascular imaging. The system integrates custom in-house robotics, proprietary ultrasound signal processing, and computational fluid dynamics to enable autonomous, semi-autonomous vascular scanning by non-specialists. It is primarily used for arteriovenous (AV) fistula mapping in dialysis patients. Note: VxWave is limited to investigational use only and is not cleared for sale by the FDA or any other regulatory authority.

Product overview

Vexev offers a single unified product, the VxWave Ultrasound Imaging System, which is a robotic tomographic ultrasound platform designed for vascular imaging. The system combines custom robotics manufactured in-house, proprietary ultrasound signal processing, and computational fluid dynamics analysis to enable autonomous vascular imaging. It is specifically designed for upper limb vascular imaging and AV fistula mapping for dialysis patients, allowing non-specialists to perform scans that previously required specialized expertise. Note: VxWave is limited to investigational use only and is not cleared for sale by the FDA or any regulatory authority.

Differentiator

Problem solved

Functional benefit

Products and services

• VxWave Ultrasound Imaging System An autonomous robotic tomographic ultrasound system for upper limb vascular imaging that enables non-specialists to perform vascular ultrasound scans. Integrates custom in-house robotics, proprietary ultrasound signal processing, machine learning, and computational fluid dynamics to create 3D vascular models and detailed reports at the point of care. Designed for arteriovenous (AV) fistula mapping in dialysis patients. Limited to investigational use only and not cleared for sale by the FDA or any other regulatory authority.

Quantifiable outcome

• High success rate and data adequacy demonstrated in CANSCAN clinical trial with 115 patients
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• U.S. Renal CarecoreStrategic or Co-development Partner · 1 November 2024U.S. Renal Care, the third-largest dialysis provider in the United States, entered into a partnership with Vexev in November 2024 for the CANSCAN clinical trial. The partnership involves using the VxWave Ultrasound Imaging System for arteriovenous (AV) fistula mapping in dialysis clinics. Dr. Geoffrey A. Block, Associate Chief Medical Officer, stated the commitment to delivering innovative treatments. This is Vexev's primary commercial pathway, with enrollment commencing for the multi-center feasibility study.
• Western Sydney VascularminorStrategic or Co-development PartnerWestern Sydney Vascular is listed as a partner on Vexev's website. The partnership likely involves clinical collaboration or vascular imaging expertise, though specific details are not provided in the available source material.
• Eastern Sydney Vascular ImagingminorStrategic or Co-development PartnerEastern Sydney Vascular Imaging is listed as a partner on Vexev's website, representing a regional clinical collaboration in vascular imaging services.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Butterfly Network: Butterfly Network builds handheld, AI-enabled point-of-care ultrasound devices (iQ) targeting similar clinical workflows including vascular access and procedural guidance. It is the closest direct peer in combining ultrasound hardware with embedded AI for non-specialist users.
• EchoNous: EchoNous develops AI-guided handheld ultrasound probes (e.g., Kosmos, Vein) used for vascular access and point-of-care imaging. It overlaps directly with Vexev's positioning of enabling non-specialists to perform vascular ultrasound scans.
• Exo Imaging: Exo Imaging produces handheld ultrasound devices with AI workflow software for point-of-care imaging, including vascular and procedural applications. It is comparable as a hardware-plus-AI ultrasound peer competing for the same clinical decision-support workflow.
• Clarius Mobile Health: Clarius manufactures wireless handheld ultrasound scanners with AI-assisted features used by clinicians at the point of care, including vascular access procedures. It is a relevant comparable on handheld AI-enabled ultrasound, though Vexev's robotic/autonomous positioning is more differentiated.

Broad incumbents

• GE HealthCare: GE HealthCare is the global leader in ultrasound systems (LOGIQ, Vscan) with deep installed bases across dialysis networks and hospital vascular labs. Its broad portfolio and R&D scale make it the dominant incumbent against which Vexev's autonomous robotic approach must differentiate.
• Philips: Philips offers the EPIQ and Affiniti ultrasound lines used widely in vascular imaging and dialysis access mapping, along with AI-driven quantification tools. It is the principal enterprise incumbent competing for the same hospital and dialysis clinic budgets.
• Siemens Healthineers: Siemens Healthineers provides the ACUSON family of ultrasound systems used in vascular and radiology workflows, with growing AI capabilities. Comparable as a broad incumbent ultrasound vendor in vascular imaging.
• FUJIFILM Sonosite: Sonosite specializes in point-of-care and procedural ultrasound, including vascular access, with strong penetration in nephrology and anesthesia. It is comparable as an established point-of-care incumbent whose workflow Vexev aims to automate.
• Mindray: Mindray is a leading global ultrasound manufacturer with a broad portfolio spanning cart-based and portable systems used in vascular and point-of-care imaging. It is comparable as a broad incumbent competing on price-performance in vascular ultrasound.

Emerging players

• HeartVista: HeartVista (now Vista AI) develops AI-driven cardiac MRI automation with similar underlying principles of autonomous image acquisition and analysis. It is a thematically adjacent emerging peer demonstrating the broader clinical appetite for autonomous, AI-driven imaging workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/vexevvascular

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vexev